Ansa Biotechnologies key facts
as of Oct 2026- Developer of a novel DNA synthesis technology designed to simplify the biological research process.
- Ansa Biotechnologies is valued at approximately $269.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $139.6M across 4 recorded rounds; the latest was Early Stage VC ($46.4M) in Jun 2024.
- Notable investors include Y Combinator, US National Science Foundation, Mubadala Investment Company, Metaplanet Holdings, RA Capital Management — 27 tracked in total.
- Ansa Biotechnologies has filed 6 Form Ds with the SEC since 2020, most recently Dec 2025 ($46.4M sold to 41 investors).
- Status: Privately Held (backing).
Valued at $269.0M at its later-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 27 names
- ·Watch Ansa Biotechnologies: the Monday email on marks, rounds and moves
Ansa Biotechnologies funding rounds
4 roundsWho backs Ansa Biotechnologies
27+Ansa Biotechnologies valuation
Ansa Biotechnologies was valued at $269 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Ansa Biotechnologies raised?
Ansa Biotechnologies has raised $140 million across 4 recorded rounds since 2020. The largest was a $68 million Series A in Apr 2022; the most recent was a $46.4 million early-stage round in Jun 2024.
Ansa Biotechnologies has filed 6 Form Ds with the SEC since 2020, most recently in Dec 2025 ($46.4 million sold to 41 investors).
Ansa Biotechnologies investors
27 investors are on record for Ansa Biotechnologies, including Y Combinator, US National Science Foundation, Mubadala Investment Company and Metaplanet Holdings. By type, the record holds 7 venture capital firms and 1 family office. The early-stage round in Jun 2024 drew 41 investors.
Comparable companies
Comparable biotechnology names by valuation on PrivateMarketView: Ambros Therapeutics ($250 million), Gameto ($243 million) and Antheia ($240 million).
About Ansa Biotechnologies
Developer of a novel DNA synthesis technology designed to simplify the biological research process. The company's enzymatic technology accelerates biological research and engineering based on polymerase-nucleotide conjugates to extend a molecule, which produces gene-length oligonucleotides, enabling medical researchers to make synthetic genes for customers as a service.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2018
- Employees
- 77
- Website
- ansabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.